febuxostat has been researched along with Liver Steatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Honda, M; Kaneko, S; Matsui, C; Mizukoshi, E; Nagashimada, M; Nagata, N; Ni, Y; Nishikawa, T; Ota, T; Sakai, Y; Shimakami, T; Shirakura, T; Xu, L; Yamashita, T; Zhuge, F | 1 |
| Hong, S; Kim, YG; Kwon, OC; Lee, CK; Lee, JS; Lee, SS; Oh, JS; Won, J; Yoo, B | 1 |
2 other study(ies) available for febuxostat and Liver Steatosis
| Article | Year |
|---|---|
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Topics: Allopurinol; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Febuxostat; Hyperuricemia; Insulin Resistance; Lipid Peroxidation; Liver; Macrophage Activation; Mice, Inbred C57BL; Molecular Targeted Therapy; Uric Acid; Xanthine Oxidase | 2020 |
Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease.
Topics: Adult; Allopurinol; Analysis of Variance; Cohort Studies; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Febuxostat; Female; Gout; Gout Suppressants; Humans; Liver; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler | 2019 |